Back to News
Market Impact: 0.4
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Source: reuters.com
Healthcare & BiotechRegulation & Legislation

Zealand Pharma received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of Zeydovio for short bowel syndrome. The recommendation is a significant regulatory milestone and improves the likelihood of eventual European commercialization for the drug candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
ZEAL0.82
More News
- Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- India forces caller-ID apps to feed spam reports to telcos